Reinacher Peter Christoph, Amtage Florian, Rijntjes Michel, Piroth Tobias, Prokop Thomas, Jenkner Carolin, Kätzler Jürgen, Coenen Volker Arnd
Department of Stereotactic and Functional Neurosurgery, Medical Center, University of Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
JMIR Res Protoc. 2018 Jan 30;7(1):e36. doi: 10.2196/resprot.8341.
Besides fluctuations, therapy refractory tremor is one of the main indications of deep brain stimulation (DBS) in patients with idiopathic Parkinson syndrome (IPS). Although thalamic DBS (ventral intermediate nucleus [Vim] of thalamus) has been shown to reduce tremor in 85-95% of patients, bradykinesia and rigidity often are not well controlled. The dentato-rubro-thalamic tract (DRT) that can directly be targeted with special diffusion tensor magnetic resonance imaging sequences has been shown as an efficient target for thalamic DBS. The subthalamic nucleus (STN) is typically chosen in younger patients as the target for dopamine-responsive motor symptoms. This study investigates a one-path thalamic (Vim/DRT) and subthalamic implantation of DBS electrodes and possibly a combined stimulation strategy for both target regions.
This study investigates a one path thalamic (Vim/DRT) and subthalamic implantation of DBS electrodes and a possibly combined stimulation strategy for both target regions.
This is a randomized, active-controlled, double-blinded (patient- and observer-blinded), monocentric trial with three treatments, three periods and six treatment sequences allocated according to a Williams design. Eighteen patients will undergo one-path thalamic (Vim/DRT) and STN implantation of DBS electrodes. After one month, a double-blinded and randomly-assigned stimulation of the thalamic target (Vim/DRT), the STN and a combined stimulation of both target regions will be performed for a period of three months each. The primary objective is to assess the quality of life obtained by the Parkinson's Disease Questionnaire (39 items) for each stimulation modality. Secondary objectives include tremor reduction (obtained by the Fahn-Tolosa-Marin tremor rating scale, video recordings, the Unified Parkinson's disease rating scale, and by tremor analysis), psychiatric assessment of patients, and to assess the safety of intervention.
At the moment, the recruitment is stopped and 12 patients have been randomized and treated. A futility analysis is being carried out by means of a conditional power analysis.
The approach of the OPINION trial planned to make, for the first time, a direct comparison of the different stimulation conditions (Vim/DRT, compared to STN, compared to Vim/DRT+STN) in a homogeneous patient population and, furthermore, will allow for intraindividual comparison of each condition with the "quality of life" outcome parameter. We hypothesize that the combined stimulation of the STN and the thalamic (Vim/DRT) target will be superior with respect to the patients' quality of life as compared to the singular stimulation of the individual target regions. If this holds true, this work might change the standardized treatment described in the previous section.
ClinicalTrials.gov: NCT02288468; https://clinicaltrials.gov/ct2/show/NCT02288468 (Archived by WebCite at http://www.webcitation.org/6wlKnt2pJ); and German Clinical Trials Register: DRKS00007526; https://www.drks.de/drks_ web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007526 (Archived by WebCite at http://www.webcitation.org/6wlKyXZZL).
除了震颤波动外,治疗难治性震颤是特发性帕金森综合征(IPS)患者深部脑刺激(DBS)的主要适应症之一。尽管丘脑DBS(丘脑腹中间核[Vim])已被证明可使85-95%的患者震颤减轻,但运动迟缓及强直往往控制不佳。可通过特殊扩散张量磁共振成像序列直接靶向的齿状红核丘脑束(DRT)已被证明是丘脑DBS的有效靶点。对于多巴胺反应性运动症状,年轻患者通常选择丘脑底核(STN)作为靶点。本研究调查DBS电极的单路径丘脑(Vim/DRT)和丘脑底核植入以及针对两个靶点区域可能的联合刺激策略。
本研究调查DBS电极的单路径丘脑(Vim/DRT)和丘脑底核植入以及针对两个靶点区域可能的联合刺激策略。
这是一项随机、活性对照、双盲(患者和观察者双盲)、单中心试验,有三种治疗方法、三个阶段和六个治疗序列,根据威廉姆斯设计进行分配。18名患者将接受DBS电极的单路径丘脑(Vim/DRT)和STN植入。1个月后,将对丘脑靶点(Vim/DRT)、STN进行双盲且随机分配的刺激,并对两个靶点区域进行联合刺激,每种刺激持续3个月。主要目的是通过帕金森病问卷(39项)评估每种刺激方式所获得的生活质量。次要目的包括震颤减轻(通过法恩-托洛萨-马林震颤评定量表、视频记录、统一帕金森病评定量表以及震颤分析获得)、患者的精神评估以及评估干预的安全性。
目前,招募已停止,12名患者已被随机分组并接受治疗。正在通过条件性效能分析进行无效性分析。
OPINION试验的方法计划首次在同质患者群体中对不同刺激条件(Vim/DRT,与STN相比,与Vim/DRT+STN相比)进行直接比较,此外,还将允许对每种条件与“生活质量”结果参数进行个体内比较。我们假设与单个靶点区域的单一刺激相比,STN与丘脑(Vim/DRT)靶点的联合刺激在患者生活质量方面更具优势。如果情况确实如此,这项工作可能会改变上一节中描述的标准化治疗。
ClinicalTrials.gov:NCT02288468;https://clinicaltrials.gov/ct2/show/NCT02288468(由WebCite存档于http://www.webcitation.org/6wlKnt2pJ);以及德国临床试验注册中心:DRKS00007526;https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007526(由WebCite存档于http://www.webcitation.org/6wlKyXZZL)。